	US 12,357,702 B2
	Peptidic diagnostic compositions
Seyed Moien Moghimi, København (DK); Linping Wu, Søborg (DK); Davoud Ahmadvand, Søborg (DK); and Ladan Parhamifar, Frederiksberg (DK)
Assigned to S. M. DISCOVERY GROUP INC., Centennial, CO (US)
Filed by S. M. Discovery Group Inc., Centennial, CO (US)
Filed on Aug. 18, 2023, as Appl. No. 18/452,479.
Application 18/452,479 is a continuation of application No. 17/301,430, filed on Apr. 2, 2021, granted, now 11,730,820.
Application 17/301,430 is a continuation of application No. 15/991,738, filed on May 29, 2018, granted, now 11,000,599, issued on May 11, 2021.
Application 15/991,738 is a continuation of application No. 14/912,997, granted, now 9,981,047, issued on May 29, 2018, previously published as PCT/EP2014/067651, filed on Aug. 19, 2014.
Claims priority of application No. PA 2013 70453 (DK), filed on Aug. 19, 2013.
Prior Publication US 2024/0131174 A1, Apr. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/66 (2017.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01); A61K 49/00 (2006.01); C12N 15/113 (2010.01)

CPC A61K 47/66 (2017.08) [A61K 47/64 (2017.08); A61K 47/69 (2017.08); A61K 47/6901 (2017.08); A61K 47/6911 (2017.08); A61K 47/6929 (2017.08); A61K 47/6953 (2017.08); A61K 49/0002 (2013.01); A61K 49/0056 (2013.01); C12N 15/113 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3513 (2013.01)]

11 Claims

1. A diagnostic composition comprising:

the peptide of SEQ ID NO: 1, the peptide of SEQ ID NO: 2, or a peptide which is at least 80% identical to the peptide of SEQ ID NOs: 1 or 2, or a pharmaceutically acceptable salt or ester thereof;

a cysteine residue at the N-terminus of the peptide; and

at least one diagnostic molecule covalently attached to an amino group of the cysteine residue.